2022 ASH Annual Meeting
Advertisement
Shambavi Richard, discusses a retrospective study on extramedullary disease and CAR-T in multiple myeloma.
Simona Soverini, PhD, discusses new molecular data on CML, remaining challenges, and potentially practice-changing data.
Sarah Tasian, MD, of the Children's Hospital of Philadelphia, talks with The HemOnc Pulse about pediatric oncology.
A simulation approach identified odronextamab dosing regimens that could be used in children with aggressive NHL.
Race/ethnicity, income, and access to chemotherapy and radiation therapy improved outcomes in patients with Burkitt lymphoma.
The cell of origin in patients with diffuse large B-cell lymphoma may impact their response to CAR-T therapy and survival.
Patients with ALL who underwent allogeneic HSCT in their first complete remission had a two-year OS rate of 73.9%.
Cachexia could be used as a prognostic marker for survival after CAR-T therapy in patients with aggressive B-cell lymphoma.
In follow-up data from the phase II CAPTIVATE study, ibrutinib plus venetoclax demonstrated a favorable benefit-risk profile.
An asparaginase-containing, pediatric-inspired regimen led to an overall survival benefit in teens and young adults with ALL.
Zanubrutinib may be “more efficacious and better tolerated” than ibrutinib for patients with relapsed/refractory CLL or ...
Amy Kirkwood, MSc, discusses results from the randomized phase III UKALL trial during the 2022 ASH Annual Meeting.
SOHO President Jennifer R. Brown, MD, PhD, speaks about the phase III ALPINE study, which compared BTK inhibitors in CLL/SLL.
The CLL2-Give trial determined that obinutuzumab, ibrutinib, and venetoclax is a “potent and promising” treatment for ...
Srdan Verstovsek, MD, discusses using machine learning to predict resistance to hydroxyurea therapy in polycythemia vera.
Patients with chronic lymphocytic leukemia (CLL) primarily rely on their physicians for information about their disease.
Patients with MPN have a high risk of death from cardiovascular causes.
Patients with MPN who are employed face a “high economic burden,” especially if they experience thrombotic events.
Statin use may reduce the risk of developing a myeloproliferative neoplasm (MPN), according to a recent study.
Chadi Nabhan, MD, MBA, FACP, interviews Srdan Verstovsek, MD, on highlights in MPN research at the 2022 ASH Annual Meeting.
Srdan Verstovsek, MD, discusses the phase III VERIFY trial of rusfertide in patients with polycythemia vera.
There has been an improvement in the prognosis of older patients diagnosed with acute lymphoblastic leukemia.
Allogeneic HSCT “remains a curative option” for certain patients with large B-cell lymphoma who relapse after CAR-T.
Robert Orlowski, MD, PhD, discusses bispecific antibodies and novel targets in myeloma with Chadi Nabhan, MD, MBA, FACP.
Mutation of CALR in patients with myelofibrosis may be associated with a more anemic phenotype at diagnosis.
The combination of acalabrutinib plus venetoclax and rituximab is well tolerated in treatment-naive MCL.
The triple chemotherapy-free combination of acalabrutinib, lenalidomide, and rituximab is well tolerated in MCL.
Jean Koff, MD, MSc, discusses research presented at ASH on the genomic characterization of mantle cell lymphoma.
Simultaneous treatment with ponatinib and blinatumomab was safe and effective in patients with newly diagnosed PH+ ALL.
Researchers have identified possible resistance mechanisms to gilteritinib plus venetoclax in patients with R/R AML.
Molecular MRD was strongly prognostic in patients with NPM1-mutated AML who received venetoclax-based non-intensive therapy.
Watch as Chadi Nabhan, MD, MBA, FACP, interviews Jeffrey Lancet, MD, about novel and targeted therapies for AML.
David Bond, MD, discusses data on survival following MCL relapse from the LION Prospective Observational Registry.
The combination of decitabine/cedazuridine, venetoclax, and an IDH1 inhibitor was effective in treating IDH-mutated AML.
Ivosidenib and azacitidine led to deep and durable remissions associated with clearance of IDH1-mutated newly diagnosed AML.
Updated results from the phase I/II BRUIN study showed that pirtobrutinib continues to be well tolerated in R/R MCL.
Survival rates for MDS/MPN overlap syndromes vary significantly by clinical entity.
A phase III trial confirmed the efficacy of lenalidomide in transfusion-dependent MDS patients.
MDS patients with del5q and one additional non-del20q cytogenetic abnormality are at higher risk.
Researchers formulated an optimal dosing schedule for the oral-fixed dose combination of decitabine and cedazuridine in MDS.
Blast quantification modalities vary substantially and could significantly impact treatment decisions in patients with MDS.
Elias Jabbour, MD, chats with The HemOnc Pulse host Chadi Nabhan, MD, MBA, FACP, about ALL treatment advances at ASH 2022.
Nicholas Short, MD, discusses updated results from a phase I/II study of a triplet combination for FLT3-mutated AML.
Christine Ryan, MD, discusses research presented at the 2022 American Society of Hematology Annual Meeting.
High-dose immunochemotherapy and AHSCT “failed to show superiority over” an ibrutinib-containing treatment without AHSCT.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.